Search results for "Progression"

showing 10 items of 1251 documents

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multice…

2018

Summary Background Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAF V600 -mutant melanoma in the COLUMBUS trial. Here, we report the results of the secondary endpoint of overall survival. Methods COLUMBUS was a two-part, randomised, open-label, phase 3 study done at 162 hospitals in 28 countries. Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma, BRAF V600E or BRAF V600K mutation, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and were treatment naive or had pr…

Male0301 basic medicineOncologySkin NeoplasmsTime FactorsMedizinPhases of clinical researchGene mutationchemistry.chemical_compound0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsVemurafenibMelanomaAged 80 and overTrametinibSulfonamides10177 Dermatology ClinicBinimetinibMiddle AgedProgression-Free SurvivalPhenotypeOncologyTolerability030220 oncology & carcinogenesisDisease ProgressionFemale2730 Oncologymedicine.drugAdultProto-Oncogene Proteins B-rafmedicine.medical_specialty610 Medicine & healthYoung Adult03 medical and health sciencesInternal medicineBiomarkers TumormedicineHumansGenetic Predisposition to DiseaseProgression-free survivalProtein Kinase InhibitorsAgedPerformance statusbusiness.industry030104 developmental biologyVemurafenibchemistryMutationBenzimidazolesCarbamatesbusinessThe Lancet Oncology
researchProduct

Shared Genetic Etiology of Obesity-Related Traits and Barrett's Esophagus/Adenocarcinoma: Insights from Genome-Wide Association Studies

2020

Abstract Background: Obesity is a major risk factor for esophageal adenocarcinoma (EA) and its precursor Barrett's esophagus (BE). Research suggests that individuals with high genetic risk to obesity have a higher BE/EA risk. To facilitate understanding of biological factors that lead to progression from BE to EA, the present study investigated the shared genetic background of BE/EA and obesity-related traits. Methods: Cross-trait linkage disequilibrium score regression was applied to summary statistics from genome-wide association meta-analyses on BE/EA and on obesity traits. Body mass index (BMI) was used as a proxy for general obesity, and waist-to-hip ratio (WHR) for abdominal obesity. …

Male0301 basic medicineOncologymedicine.medical_specialtyEsophageal NeoplasmsEpidemiologyQuantitative Trait LocieducationMedizinMEDLINEGenome-wide association studyAdenocarcinomaPolymorphism Single NucleotideRisk AssessmentLinkage DisequilibriumBody Mass IndexBarrett Esophagus03 medical and health sciencesSex Factors0302 clinical medicineMeta-Analysis as TopicRisk FactorsInternal medicineHumansMedicineGenetic Predisposition to DiseaseObesityEsophagusWaist-Hip Ratiobusiness.industryEsophageal cancermedicine.diseaseMedical researchObesityRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisBarrett's esophagusDisease ProgressionAdenocarcinomaFemalebusinessGenome-Wide Association StudyCancer Epidemiology, Biomarkers & Prevention
researchProduct

Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment

2016

// Marta Jessica Llorca-Cardenosa 1, * , Tania Fleitas 1, * , Maider Ibarrola-Villava 1 , Maria Pena-Chilet 1 , Cristina Mongort 2 , Carolina Martinez-Ciarpaglini 2 , Lara Navarro 2 , Valentina Gambardella 1 , Josefa Castillo 1 , Susana Rosello 1 , Samuel Navarro 2 , Gloria Ribas 1 , Andres Cervantes 1 1 Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain 2 Department of Pathology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain * These authors contributed equally to this work Correspondence to: Gloria Ribas, email: gribas@incliva.es Andres Cervantes, email: andres.cervantes@uv.es Keywords: RUNX3, ARID1A, gastric ca…

Male0301 basic medicineRUNX3immune microenvironmentBiologyEpigenesis Genetic03 medical and health sciences0302 clinical medicineStomach NeoplasmsCDKN2ABiomarkers TumorTumor MicroenvironmentmedicineHumansEpigeneticsPromoter Regions GeneticAgedAged 80 and overTumor microenvironmentgastric cancerMicrosatellite instabilityCancerMethylationDNA MethylationMiddle AgedPrognosismedicine.diseaseARID1Adigestive system diseasesSurvival RateCore Binding Factor Alpha 3 Subunit030104 developmental biologyOncologyTumor progressionCase-Control Studies030220 oncology & carcinogenesisDNA methylationImmunologyCancer researchCpG IslandsFemaleMicrosatellite InstabilityFollow-Up StudiesResearch Papergene methylationOncotarget
researchProduct

Lipidomic profiling identifies signatures of metabolic risk

2020

Background: Metabolic syndrome (MetS), the clustering of metabolic risk factors, is associated with cardiovascular disease risk. We sought to determine if dysregulation of the lipidome may contribute to metabolic risk factors. Methods: We measured 154 circulating lipid species in 658 participants from the Framingham Heart Study (FHS) using liquid chromatography-tandem mass spectrometry and tested for associations with obesity, dysglycemia, and dyslipidemia. Independent external validation was sought in three independent cohorts. Follow-up data from the FHS were used to test for lipid metabolites associated with longitudinal changes in metabolic risk factors. Results: Thirty-nine lipids were…

Male0301 basic medicineResearch paperdhSL dihydrosphingolipidBMI body mass indexlcsh:MedicineATHEROGENIC LIPOPROTEINSBioinformaticsFHS Framingham Heart StudyPC phosphatidylcholinePESA Progression of Early Subclinical Atherosclerosis0302 clinical medicineFramingham Heart StudyRisk FactorsSAFHS San Antonio Family Heart StudyLC-MS/MS liquid chromatography-tandem mass spectrometryMedicineLongitudinal StudiesMetabolic riskPLASMA SPHINGOLIPID METABOLISMPOPULATIONlcsh:R5-920education.field_of_studySPHINGOMYELINCE cholesteryl esterDysglycemiaGeneral MedicineMiddle AgedLipidomePS phosphatidylserineCardiovascular diseaseLipidsMetabolic syndrome3. Good healthCARDIOVASCULAR-DISEASE030220 oncology & carcinogenesisHEARTMetS metabolic syndromeFemaleDisease SusceptibilityLGPL lysoglycerophospholipidSL sphingolipidlcsh:Medicine (General)LPE lysophosphatidylethanolamineAdultFDR false discovery rateTAG triacylglycerolPopulationCer ceramideCVD cardiovascular diseasePE phosphatidylethanolamineDENSITY-LIPOPROTEINRisk AssessmentGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesAnimalsHumanseducationT2DM type II diabetes mellitusAgedLPC lysophosphatidylcholineSM sphingomyelinbusiness.industryCERAMIDElcsh:RHDL-C High density lipoprotein cholesterolBiomarkerLipid Metabolismmedicine.diseaseObesitySphingolipidCross-Sectional Studies030104 developmental biologyDyslipidemiaERF Erasmus Family StudyLipidomicsMetabolic syndromeINDUCED INSULIN-RESISTANCEbusinessDAG diacylglycerolBody mass indexBiomarkersDyslipidemiaMRM multiple reaction monitoringFASTING GLUCOSE
researchProduct

Downregulation of intratumoral expression of miR-205, miR-200c and miR-125b in primary human cutaneous melanomas predicts shorter survival

2018

AbstractWhile only 15–25 percent of melanoma patients develop distant metastasis and die, this disease is still responsible for the majority of skin cancer-related deaths. The availability of adjuvant therapies makes the selection of high-risk patients essential. We evaluated the intratumoral expression of ten miRNAs in primary melanomas in relation to its ability to predict melanoma survival. To this end, we correlated miRNA expression in 132 cryopreserved primary and metastatic tumors with clinicopathological factors and clinical outcome. We found sequential downregulation of intratumoral expression of miR-125b, miR-182, miR-200c and miR-205 over the full spectrum of melanoma progression.…

Male0301 basic medicineSkin Neoplasmsmedicine.medical_treatmentlcsh:MedicineDown-RegulationDiseaseArticleMetastasisExtracellular matrix03 medical and health sciences0302 clinical medicineDownregulation and upregulationCell MovementmicroRNABiomarkers TumorTumor Cells CulturedmedicineHumansNeoplasm Invasivenesslcsh:ScienceMelanomaAgedCell ProliferationMultidisciplinarybusiness.industryMelanomalcsh:RPrognosismedicine.diseaseIn vitroGene Expression Regulation NeoplasticSurvival RateMicroRNAs030104 developmental biology030220 oncology & carcinogenesisDisease ProgressionCancer researchlcsh:QFemalebusinessAdjuvantFollow-Up StudiesScientific Reports
researchProduct

Electrocortical networks in Parkinson's disease patients with Mild Cognitive Impairment. The PaCoS study

2019

Abstract Introduction Parkinson's Disease (PD) is frequently associated with cognitive dysfunction ranging from Mild Cognitive Impairment (PD-MCI) to dementia. Few electrophysiological studies are available evaluating potential pathogenetic mechanisms linked to cognitive impairment in PD since its initial phases. The objective of the study is to analyze electrocortical networks related with cognitive decline in PD-MCI for identifying possible early electrophysiological markers of cognitive impairment in PD. Methods From the PaCoS (Parkinson's disease Cognitive impairment Study) cohort, a sample of 102 subjects including 46 PD-MCI and 56 PD with normal cognition (PD-NC) was selected based on…

Male0301 basic medicinemedicine.medical_specialtyParkinson's diseaseQuantitative EEGElectroencephalographyAudiology03 medical and health sciences0302 clinical medicinemental disordersmedicineHumansDementiaCognitive DysfunctionNeuropsychological assessmentCognitive declineTomographyAgedElectrocortical networkElectrocortical networksmedicine.diagnostic_testbusiness.industryParietal lobeMild cognitive impairmentElectroencephalographyParkinson DiseaseCognitionMiddle Agedmedicine.disease030104 developmental biologyNeurologyFrontal lobeDisease ProgressionFemaleNeurology (clinical)Nerve NetElectrocortical networks; Mild cognitive impairment; Parkinson's disease; Quantitative EEG; Neurology; Geriatrics and Gerontology; Neurology (clinical)Geriatrics and GerontologyOccipital lobebusiness030217 neurology & neurosurgeryParkinsonism & Related Disorders
researchProduct

Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines…

2016

Palmitoylethanolamide (PEA) is an endogenous lipid mediator known to reduce pain and inflammation. However, only limited clinical studies have evaluated the effects of PEA in neuroinflammatory and neurodegenerative diseases. Multiple sclerosis (MS) is a chronic autoimmune and inflammatory disease of the central nervous system. Although subcutaneous administration of interferon (IFN)-β1a is approved as first-line therapy for the treatment of relapsing–remitting MS (RR-MS), its commonly reported adverse events (AEs) such as pain, myalgia, and erythema at the injection site, deeply affect the quality of life (QoL) of patients with MS. In this randomized, double-blind, placebo-controlled study,…

Male0301 basic medicinemyalgiaErythemaAnti-Inflammatory AgentsPalmitic AcidAdministration OralPharmacologyGastroenterologychemistry.chemical_compound0302 clinical medicineNeuroinflammationFAAHEthanolaminePharmacology (medical)SkinInterleukin-17food and beveragesAnti-Inflammatory AgentTolerabilityEthanolaminesDisease ProgressionCytokinesOriginal ArticleFemalemedicine.symptomInterferon beta-1aHumanAdultmedicine.medical_specialtyPainPalmitic AcidsProinflammatory cytokineInterferon-gamma03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingDouble-Blind MethodInternal medicinemedicineHumansAdverse effectCytokinePharmacologyPalmitoylethanolamideExpanded Disability Status ScaleTumor Necrosis Factor-alphabusiness.industryMultiple sclerosisN-acylethanolamineOleoylethanolamideAnandamideNAAAmedicine.diseaseAmides030104 developmental biologychemistryNeurology (clinical)business030217 neurology & neurosurgeryNeurotherapeutics
researchProduct

Retinal and choroidal vasculature changes associated with chronic kidney disease

2018

Retinal and choroidal microvascular changes can be related to renal impairment in hypertension and chronic kidney disease (CKD). The study examines the association between retinochoroidal parameters and renal impairment in hypertensive, non-diabetic patients. This is a cross-sectional study on Caucasian patients with systemic arterial hypertension with different levels of renal function. All subjects were studied by blood chemistry, urine examination, microalbuminuria and blood pressure. Complete eye examination was completed with swept source optical coherence tomography (SS-OCT) and optical coherence tomography angiography (OCTA) scans of macular region. Patients were divided in groups: L…

Male030204 cardiovascular system & hematologyurologic and male genital diseaseschemistry.chemical_compound0302 clinical medicineFluorescein AngiographyMiddle Agedfemale genital diseases and pregnancy complicationsSensory Systemschoroidal thickness chronic kidney disease vascular density retinal thickness swept source OCTA swept source OCT angiographyHypertensionDisease ProgressionFemalemedicine.symptomTomography Optical CoherenceAdultmedicine.medical_specialtyAdolescentFundus OculiRenal function03 medical and health sciencesCellular and Molecular NeuroscienceYoung AdultRetinal DiseasesOphthalmologymedicineHumansRenal Insufficiency ChronicRetinal thinningAgedRetrospective StudiesSettore MED/14 - Nefrologiabusiness.industryChoroidSettore MED/30 - Malattie Apparato VisivoRetinal VesselsRetinalmedicine.diseaseeye diseasesOphthalmologyBlood pressureCross-Sectional StudieschemistryBlood chemistry030221 ophthalmology & optometryAlbuminuriaMicroalbuminuriasense organsbusinessKidney disease
researchProduct

“Better explanations” in multiple sclerosis diagnostic workup

2019

BackgroundThe exclusion of other diseases that can mimic multiple sclerosis (MS) is the cornerstone of current diagnostic criteria. However, data on the frequency of MS mimics in real life are incomplete.MethodsA total of 695 patients presenting with symptoms suggestive of MS in any of the 22 RIREMS centers underwent a detailed diagnostic workup, including a brain and spinal cord MRI scan, CSF and blood examinations, and a 3-year clinical and radiologic follow-up.FindingsA total of 667 patients completed the study. Alternative diagnoses were formulated in 163 (24.4%) cases, the most frequent being nonspecific neurologic symptoms in association with atypical MRI lesions of suspected vascular…

Male404241Longitudinal StudieDisease0302 clinical medicineMultiple SclerosiDiagnosisMedicine030212 general & internal medicineProspective StudiesLongitudinal StudiesProspective cohort studymedicine.diagnostic_testMagnetic Resonance Imagingclinical practiceatypical MRI lesionsMS mimicsDisease ProgressionFemaleSettore MED/26 - NeurologiaRadiologyHumanAdultmultiple sclerosis; diagnostic criteria; atypical MRI lesions; MS mimics; clinical practicemedicine.medical_specialtyMultiple Sclerosis2omarkers / metabolism Diagnosis Differential Female Follow-Up Studies Humans Longitudinal Studies Magnetic Resonance Imaging Male Multiple Sclerosis / diagnosis* Prospective StudiesArticleFollow-Up StudieDiagnosis Differential03 medical and health sciencesHumansNeuromyelitis opticabusiness.industryMultiple sclerosisAdult; Biomarkers; Diagnosis Differential; Female; Follow-Up Studies; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Prospective StudiesMagnetic resonance imagingOdds ratioBiomarkermedicine.disease101MigraineDifferentialdiagnostic criteriaNeurology (clinical)Differential diagnosisbusiness030217 neurology & neurosurgeryBiomarkersFollow-Up StudiesNeurology
researchProduct

Occult hepatitis B virus infection

2000

Many studies have shown that hepatitis B virus infection may also occur in hepatitis B surface antigen-negative patients. This occult infection has been identified both in patients with cryptogenic liver disease and in patients with hepatitis C virus-related chronic hepatitis, and much evidence suggests that it may be a risk factor of hepatocellular carcinoma development. However several aspects of this occult infection remain unclear such as its prevalence and the factor(s) involved in the lack of circulating hepatitis B surface antigen. Moreover, it is uncertain whether the occult hepatitis B virus infection may contribute to chronic liver damage, considering that it is usually associated…

MaleACUTE VIRAL-HEPATITISPOSTTRANSFUSION HEPATITISHBV SURFACE-ANTIGENComorbidityHBV genome HBsAg-negative liver DNA liver diseasemedicine.disease_causeSeverity of Illness IndexSEROLOGICAL MARKERS; TRANSPLANT RECIPIENTS; POSTTRANSFUSION HEPATITIS; HEPATITIS C VIRUS; HEPATOCELLULAR-CARCINOMA; HBV SURFACE-ANTIGEN; ACUTE VIRAL-HEPATITIS; CHRONIC LIVER-DISEASE; POLYMERASE CHAIN-REACTION; occult hepatitis B virus infectionLiver diseaseCHRONIC LIVER-DISEASEHEPATOCELLULAR-CARCINOMAChronic/diagnosis* Hepatitis BDifferential Disease Progression Female Hepatitis B Surface Antigens/analysis* Hepatitis Bhbsag-negative; hbv genome; liver disease; liver dnaIncidenceHepatocellular/diagnosis CarcinomaLiver NeoplasmsGastroenterologyHepatitis CHepatitis BPOLYMERASE CHAIN-REACTIONPrognosisChronic/epidemiology* Humans Incidence Liver Neoplasms/diagnosis Liver Neoplasms/epidemiology* Male Prognosis Risk Assessment Severity of Illness IndexCarcinoma Hepatocellular/diagnosis Carcinoma Hepatocellular/epidemiology* Comorbidity DNA Viral/analysis Diagnosis Differential Disease Progression Female Hepatitis B Surface Antigens/analysis* Hepatitis B Chronic/diagnosis* Hepatitis B Chronic/epidemiology* Humans Incidence Liver Neoplasms/diagnosis Liver Neoplasms/epidemiology* Male Prognosis Risk Assessment Severity of Illness IndexHepatocellular carcinomaDisease Progressionhbv genomeFemaleliver diseaseCarcinoma HepatocellularTRANSPLANT RECIPIENTSRisk AssessmentDiagnosis Differentialoccult hepatitis B virus infectionHepatitis B ChronicViral/analysis DiagnosismedicineHumansRisk factorHepatitis B virusHepatitis B Surface AntigensHepatologybusiness.industryCarcinomaHEPATITIS C VIRUShbsag-negativeliver dnamedicine.diseaseOccultVirologyHepatocellular/epidemiology* Comorbidity DNASEROLOGICAL MARKERSViral replicationImmunologyDNA Viralbusiness
researchProduct